VCYT

33.15

1.66% -0.56

Pre-mercato: 33.15

Veracyte Inc (VCYT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$33.71

Aprire:

$33.75

Volume 24 ore:

807.53K

Relative Volume:

0.90

Capitalizzazione di mercato:

$2.63B

Reddito:

$517.15M

Utile/perdita netta:

$66.35M

Rapporto P/E:

40.37

EPS:

0.8212

Flusso di cassa netto:

$126.63M

1 W Prestazione:

+0.36%

1M Prestazione:

-1.16%

6M Prestazione:

-6.99%

1 anno Prestazione:

+5.36%

Intervallo 1D:

$31.95

$33.90

Intervallo di 1 settimana:

$31.95

$34.63

Portata 52W:

$22.61

$50.71

Veracyte Inc Stock (VCYT) Company Profile

Nome

Veracyte Inc

Settore

Healthcare (1111)

Industria

Diagnostics & Research (52)

Telefono

(650) 243-6300

Indirizzo

6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA

Dipendente

755

Cinguettio

@veracyte

Prossima data di guadagno

2026-05-05

Ultimi documenti SEC

VCYT's Discussions on Twitter

Compare VCYT vs TMO, DHR, IDXX, A, WAT

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VCYT Veracyte Inc	33.15	2.66B	517.15M	66.35M	126.63M	0.8212
TMO Thermo Fisher Scientific Inc	466.70	194.94B	44.56B	6.72B	6.29B	17.74
DHR Danaher Corp	178.57	137.69B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	560.93	45.19B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	114.42	34.50B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	311.20	32.91B	3.17B	642.63M	516.49M	10.77

Veracyte Inc Stock (VCYT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-13	Iniziato	Jefferies	Buy
2025-12-02	Ripresa	Morgan Stanley	Underweight
2025-10-20	Iniziato	Canaccord Genuity	Hold
2025-03-20	Iniziato	Craig Hallum	Buy
2024-12-05	Downgrade	Goldman	Buy → Neutral
2024-11-15	Iniziato	Wolfe Research	Outperform
2024-10-16	Iniziato	UBS	Buy
2024-10-10	Iniziato	Guggenheim	Buy
2024-02-23	Reiterato	Needham	Buy
2023-01-18	Downgrade	Raymond James	Outperform → Mkt Perform
2023-01-05	Iniziato	Scotiabank	Sector Outperform
2022-01-07	Iniziato	Stephens	Overweight
2021-11-18	Ripresa	Goldman	Buy
2021-06-15	Iniziato	Raymond James	Outperform
2021-02-18	Ripresa	Needham	Buy
2021-01-28	Iniziato	Truist	Buy
2020-11-10	Iniziato	KeyBanc Capital Markets	Sector Weight
2020-09-09	Iniziato	Morgan Stanley	Underweight
2019-07-31	Iniziato	Lake Street	Buy
2019-07-02	Iniziato	Needham	Buy
2018-11-29	Downgrade	Janney	Buy → Neutral
2018-10-31	Aggiornamento	Janney	Neutral → Buy
2017-11-07	Downgrade	Janney	Buy → Neutral
2017-11-07	Downgrade	Piper Jaffray	Overweight → Neutral
2017-08-31	Ripresa	BTIG Research	Buy
2016-11-14	Ripresa	Leerink Partners	Outperform
2015-12-18	Iniziato	Cantor Fitzgerald	Buy
2015-06-11	Reiterato	Leerink Partners	Outperform
2013-11-26	Iniziato	William Blair	Outperform

Mostra tutto

Veracyte Inc Borsa (VCYT) Ultime notizie

02:00 AM

Emerging Sub-Segments Transforming the Thyroid Cancer Diagnostics Market Landscape - openPR.com

02:00 AM

Apr 23, 2026

Veracyte (VCYT) down 15.4% since last earnings report: Can it rebound? - MSN

Apr 23, 2026

Apr 22, 2026

VCYT Veracyte delivers triple digit Q4 2025 EPS beat and 16 percent annual revenue growth despite mild stock dip.EBITDA Margin - Xã Châu Thành

Apr 22, 2026

Veracyte (NASDAQ: VCYT) asks investors to back directors, auditor and larger equity plan - Stock Titan

Apr 22, 2026

Apr 21, 2026

Emerging Growth Patterns Driving Expansion in the Liquid Biopsy for Cancer Diagnostics Market - openPR.com

Apr 21, 2026

Apr 20, 2026

VCYT Maintained by Canaccord Genuity -- Price Target Lowered to $40 - GuruFocus

Apr 20, 2026

CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Cuts Target Price to $40 - Moomoo

Apr 20, 2026

Veracyte Price Target Cut to $40.00/Share From $43.00 by Canaccord Genuity - Moomoo

Apr 20, 2026

Apr 19, 2026

Is Veracyte (VCYT) Offering Value After Mixed Returns And Conflicting Valuation Signals - Yahoo Finance

Apr 19, 2026

Apr 16, 2026

Assessing Veracyte (VCYT) Valuation After A Recent Share Price Rebound - Sahm

Apr 16, 2026

Sumitomo Mitsui Trust Group Inc. Sells 224,185 Shares of Veracyte, Inc. $VCYT - MarketBeat

Apr 16, 2026

Apr 15, 2026

Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026 - BioSpace

Apr 15, 2026

Apr 14, 2026

Veracyte to Release Q1 2026 Results on May 5 - National Today

Apr 14, 2026

Veracyte to Release Q1 2026 Earnings on May 5 - National Today

Apr 14, 2026

Veracyte (NASDAQ: VCYT) awards 44,221 RSUs to Chief Dev and Tech Officer - Stock Titan

Apr 14, 2026

Jefferies Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $45 - 富途牛牛

Apr 14, 2026

Veracyte (NASDAQ:VCYT) Coverage Initiated at Jefferies Financial Group - MarketBeat

Apr 13, 2026

Jefferies Initiates Veracyte at Buy With $45 Price Target - marketscreener.com

Apr 13, 2026

Jefferies initiates Veracyte stock with buy on diagnostics growth - Investing.com UK

Apr 13, 2026

Jefferies initiates Veracyte stock with buy on diagnostics growth By Investing.com - Investing.com Canada

Apr 13, 2026

Apr 12, 2026

Veracyte | 4: Statement of changes in beneficial ownership of securities-Officer Wygant Jonathan - Moomoo

Apr 12, 2026

Apr 11, 2026

VCYT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 11, 2026

Apr 10, 2026

Sentiment Watch: Can Veracyte Inc be the next market leaderPortfolio Gains Report & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026